Protocol No
MERCK-MK1084-001
Staff Member
Jonathan Thompson
Phase
I
Summary
This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Objective
This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer,
Kidney,
Other Skin,
Thoracic Cancers,
Sarcoma,
Gastrointestinal Cancers,
Cervix,
Prostate and Urologic Cancers,
Other Gynecologic,
Breast Cancers,
Ovary,
Gynecologic Cancers,
Head and Neck Cancers,
Early Phase/Multiple Disease Site Cancers,
Endocrine Cancers,
Melanoma, Skin,
Eye/Orbital Cancers,
Skin Cancers
ClinicalTrials.gov